Nanomaterial Strategies for Antibiotic-Resistant Infections: Mechanistic Frameworks, Rational Design, and Clinical Translation

Antimicrobial resistance drives substantial global morbidity and mortality, yet conventional antibiotics often fail against rapidly disseminated planktonic sepsis, intracellular reservoirs that evade exposure, and biofilm- or device-associated infections that are prone to relapse. Nanomaterials offer an interface-centered, multitarget strategy that combines direct antibacterial activity with precision delivery and host modulation. We organize the field around an infection cascade spanning surface precolonization, adhesion and invasion, microcolony formation and biofilm maturation, intracellular persistence, and tissue spread or relapse. Each stage maps to auditable design modules, including membrane permeabilization, modulation of proton-motive force and efflux, matrix penetration and remodeling, targeted intracellular release, and host-directed immunoregulation. Two complementary design logics anchor this framework: intrinsically antibacterial platforms and nanocarriers that potentiate legacy antibiotics through stimuli-responsive release or externally actuated spatiotemporal control. Evidence is evaluated through quantitative readouts linking mechanisms to outcomes, including bacterial burden reduction, biofilm remodeling, intracellular clearance, and relapse-related endpoints. We further outline theranostic loops that integrate localization, activation, and response assessment and propose translational milestones, including batch-comparable critical quality attributes, controlled ionic and oxidative outputs, stable protein-corona behavior, pharmacokinetics in poorly perfused compartments, and regulatory alignment beyond the in vitro minimum inhibitory concentration.